Jim Allison, immunotherapy researcher at MD Anderson and Nobel Prize recipient, is the subject of a new film that premiered at SXSW. Photo courtesy of MD Anderson Cancer Center

For most of his career, James Allison has been a cancer research wildcatter fighting an oftentimes lonely battle for the advancement of immunotherapy. The medical community has historically been skeptical of the science, but nonetheless Allison dedicated his life to developing a better treatment to the disease that has claimed so many lives — including his mother's.

Last year, Allison, the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson, won the 2018 Nobel Prize in medicine, and Breakthrough, a film about Allison's progression from early researcher to Nobel Prize recipient, premiered on March 9 at the 2019 SXSW Interactive festival.

But despite the Nobel Prize and the new film both validating the science to the public, Allison says there's a lot more work to be done in immunotherapy. Allison, his colleague, Padmanee Sharma, and the filmmaker for Breakthrough, Bill Haney, hosted a discussion at SXSW about the future of immunotherapy.

"It's a time of considerable optimism — and we're just at the beginning," says Allison.

The film focuses on the man behind the science — a 70-year-old, harmonica-playing researcher from small-town Alice, Texas. It's both an ode to Allison's career and a thought-provoking take on all the work left to be done in the industry.

Immunotherapy is the process of targeting one's immune system's T-cells, infection-fighting white blood cells, to attack cancer cells. Sharma, a fellow MD Anderson oncology expert and clinician, says their work has received clinical approvals for treating Melanoma, kidney cancer, lung cancer, and bladder cancer. The scientists are now focused on expanding that treatment to other cancer types and building upon the established platform they've created, while also making sure nothing comes in the way of the facts of the science.

"It really requires that we dedicate ourselves to the basic science, understanding it and educating people about it, so we don't allow the facts and science get muddied by things that are political or nonfactual," Sharma says.

In a lot of ways, this is what Breakthrough has been able to do — communicate the facts on a platform where anyone can understand the science.

"We have a revolution on our hands, and thankfully we have people like Bill who can really tell the story well, because maybe as a scientist and a clinician, we're not always equally talented on telling the story to laypeople," Sharma says.

Moving forward, Allison says he's focused on finding out why the treatment fails in some instances, and he's determined to progress immunotherapy's success rate from the 20 to 40 percent rate he says he sees it at now to 100 percent.

"We've got all the basic tools, and we know what the main issues are," Allison says. "There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

University of Houston med school secures full accreditation

med school milestone

The University of Houston’s Tilman J. Fertitta Family College of Medicine has officially earned full accreditation after launching six years ago.

The designation comes from the Liaison Committee on Medical Education, which granted UH the maximum five-year review period available to a new medical school. To achieve the status, the committee reviewed the Fertitta College of Medicine's facilities, faculty and student outcomes, and curriculum to ensure the college met the highest standards in medical education.

“Full accreditation is not the finish line — it’s the foundation for everything we hope to accomplish in the years ahead,” Dr. Jonathan McCullers, vice president for health affairs at UH and dean of the Fertitta College of Medicine, said in a news release. “It strengthens our ability to attract outstanding students and faculty, expand our partnerships and prepare the next generation of physicians.”

Fertitta College of Medicine has graduated three classes of physicians, and every graduate from its most recent class secured a residency position. Enrollment has expanded from 30 students in its inaugural class to 65 students in its current class.

According to UH, about 70 percent of graduates have chosen to remain in Texas for further training, which is key to addressing the estimated 10,000 doctors needed to meet growing needs.

Fertitta College of Medicine opened for its first students in 2020, and now joins 14 other Texas schools as a fully LCME-accredited medical school. It also joins UTHealth Houston's McGovern Medical School and Baylor College of Medicine as one of three Houston-based LCME-accredited campuses.

The news comes after UH launched its health enterprise initiative, UH Health, in July and broke ground on its $77.5 million Medical Research Building next to the Fertitta College of Medicine last month.

“Building a medical school from the ground up is an extraordinary undertaking, and this milestone reflects the dedication of everyone who helped make it happen,” Dr. Stephen Scott, vice dean for education at the Fertitta College of Medicine, added in the release. “From developing an innovative curriculum to establishing the systems and partnerships that support our students, this has been a true team effort.”

Woodlands startup Mavria raises $130M to mass-produce AI data centers

seed funding

The Woodlands-based Mavria, which mass-produces factory-built modular AI data centers, just emerged from stealth mode with $130 million in funding at a $1 billion valuation.

Mavria raised the money in pre-seed and seed rounds led by Paradigm, an investment firm that concentrates on early-stage startups developing “pioneer” technology. Participants in the funding rounds include AMP PBC, Critical Frontier, Dream Ventures and Liquid 2 Ventures, co-founded by former NFL quarterback Joe Montana.

The company’s inaugural product, Terrain, is a prefabricated data center designed for AI labs, cloud computing providers and data center developers. Mavria says its platform avoids ground-up construction, delivering infrastructure more quickly and at a lower cost.

Mavria tells the Wall Street Journal that the first Terrain unit is being built at a Houston-area factory. The 5-megawatt Terrain system features power distribution, direct liquid cooling, controls and server racks.

“America sets the pace at the intelligence frontier. But the race is moving from the lab into the physical world,” Adam Blake, co-founder and CEO of Mavria, wrote in a blog post.

“Intelligence needs data centers. Data centers need power. Power needs factories, equipment, supply chains, and skilled workers, but much of that infrastructure is still built one custom project at a time, on timelines measured in years.”

Blake and Mavria’s two other co-founders, Nick Poradek and Seth Cohen, most recently worked at the U.S. Department of Energy. There, they focused on reforming the nuclear power sector.

From start to finish, it can take roughly three to six years to build a data center at an estimated cost of $10 million to $37 million per megawatt. Based on those figures, a 100-megawatt data center might cost as much as $3.7 billion.

Here are brief bios of Blake, Poradek and Cohen, who co-founded Mavria in May.

Adam Blake

Blake most recently was a senior advisor to U.S. Energy Secretary Chris Wright. He is co-founder and former CEO of Zego, a provider of energy management technology for property managers. Zego spun out from Brightergy, a commercial solar company. Blake is founder and former CEO of Brightergy.

Nick Poradek

Poradek, chief operating officer at Mavria, was also an advisor to the U.S. energy secretary. He is founder and former CEO of Spring-based Edera Energy, co-founder of The Woodlands-based craft-ice brand Clarity Ice, and founder and former CEO of The Woodlands-based Edera Capital. Poradek sold Edera Energy, a manufacturer of oilfield equipment, to Liberty Energy, a fracking company. Wright is Liberty’s founder and former chairman and CEO.

Seth Cohen

Cohen, chief strategy officer and chief legal officer at Mavria, was head of nuclear law and policy at the Department of Energy. He is also a former NASA advisor and a former attorney at Kirkland & Ellis.

“We believe in rapidly deploying infrastructure as a product, rather than custom-building every project,” Blake said. “We’re bringing together engineering, manufacturing, supply chains and capital so that every project makes us better at delivering the next.”